On Nov. 7, 2019, Ceres Nanosciences announced the commercial launch of the Nanotrap Virus Capture Kit. The Nanotrap concentrates whole virus particles from complex biological matrices, resulting in high quality input material for a range of downstream analytical methods, including multiplex nucleic acid assays, protein assays, and infectivity assays.

Ceres has been working with leading infectious disease labs for several years to optimize this technology for virus applications, which has led to several important publications in the field.

Ceres is launching the Nanotrap Virus Capture Kit at the Association of Molecular Pathology 2019 Annual Meeting & Expo in Baltimore, MD with data demonstrating increased nucleic acid yield and compatibility with multiple commercial nucleic acid kits for influenza virus samples, as well as an application note demonstrating the use of the Nanotrap Virus Particles to improve detection of Zika virus in urine samples. Ceres and its collaborators have also demonstrated how the Nanotrap technology can be used to improve non-molecular assays including protein assays and infectivity assays.